MannKind: The Saga Of Smoking Guns Feb. 3, 2017 12:05 PM ET Looking For Diogenes •MannKind has taken the reverse split approach to salvage their listing on Nasdaq. •MannKind has told investors there is an efficacy issue and now they tell you why there is this issue. •Asking for a label change for a fast-acting insulin designation carries a major downside that questions the future marketing for Afrezza. http://seekingalpha.com/article/4042502-mannkind-saga-smoking-guns?app=1&auth_param=1vat:1c99e32:1005a4fc7d0fd11db17c76357c316d7e&uprof=51